Many subcutaneous drugs are administered via an easy to use pen injector device ... Ascendis. His comment was extremely helpful in that it brought into focus what differentiates TransCon CNP ...

If approved, TransCon CNP would have a key dosing advantage over BioMarin's Voxzogo (vosoritide) given that the latter is given daily. Ascendis is up ~19% on the data. Ascendis Pharma Takes A Big ...

A slide presentation with these data can be found on the Investor Relations & News section of the Ascendis Pharma website: https://investors.ascendispharma.com. TransCon CNP demonstrated a ...

• Data demonstrate significant improvements in well-being and physical functioning compared to placebo in patients treated for 1 year with TransCon CNP at the pivotal 100µg/kg/week dose ...

16, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced topline data from the pivotal double-blind placebo-controlled ApproaCH Trial of TransCon CNP (navepegritide), which ...

Early data indicates that TransCon CNP could challenge Voxzogo's market share by late 2025. Ascendis' TransCon CNP stands out due to its once-weekly dosing schedule and potentially improved safety ...

Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has submitted its New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) for TransCon CNP (navepegritide) for the ...

Ascendis Pharma has ... that need with its CNP analog Voxzogo—the centerpiece of its growth strategy—but that drug needs to be injected once a day. Ascendis’ TransCon CNP could challenge ...

Ascendis Pharma A/S ASND shares ended the last trading ... which evaluated its investigational once-weekly administered TransCon CNP in children aged two to 11 years with achondroplasia, the ...

Also Read: Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In. In the trial, children treated with once-weekly TransCon CNP demonstrated annualized growth ...

Ascendis Pharma’s President and Chief Executive Officer. “We look forward to potential approvals of our third product, TransCon CNP, as a monotherapy in children with achondroplasia ...